{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:56:49Z","timestamp":1790377009212,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clgc.2024.01.019","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T01:12:01Z","timestamp":1706836321000},"page":"102047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-8862","authenticated-orcid":false,"given":"Jose C.","family":"Tapia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya","family":"Bosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6385-3519","authenticated-orcid":false,"given":"Javier","family":"Gavira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alejandra","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-4973","authenticated-orcid":false,"given":"Judit","family":"Sanz-Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Martin-Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Anguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2024.01.019_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2024.01.019_bib0002","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.019_bib0003","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.juro.2015.06.115","article-title":"Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond\u2014a comprehensive review of the current literature","volume":"195","author":"Oing","year":"2016","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.clgc.2024.01.019_bib0004","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.01.019_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up \u2606","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.01.019_bib0006","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"issue":"10122","key":"10.1016\/j.clgc.2024.01.019_bib0007","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet North Am Ed"},{"issue":"9","key":"10.1016\/j.clgc.2024.01.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.01.019_bib0009","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.01.019_bib0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.01.019_bib0011","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to avelumab for urothelial carcinoma. Accessed December 4, 2022. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-avelumab-urothelial-carcinoma."},{"key":"10.1016\/j.clgc.2024.01.019_bib0012","unstructured":"U.S. Food and Drug Administration. Pembrolizumab (Keytruda): advanced or metastatic urothelial carcinoma. Accessed December 4, 2022. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-advanced-or-metastatic-urothelial-carcinoma."},{"key":"10.1016\/j.clgc.2024.01.019_bib0013","unstructured":"U.S. Food and Drug Administration. Nivolumab for treatment of urothelial carcinoma. Accessed December 4, 2022. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/nivolumab-treatment-urothelial-carcinoma."},{"key":"10.1016\/j.clgc.2024.01.019_bib0014","unstructured":"Tecentriq | European Medicines Agency. Accessed January 21, 2024. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecentriq."},{"key":"10.1016\/j.clgc.2024.01.019_bib0015","unstructured":"Keytruda | European Medicines Agency. Accessed January 21, 2024. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/keytruda."},{"key":"10.1016\/j.clgc.2024.01.019_bib0016","unstructured":"Opdivo | European Medicines Agency. Accessed January 21, 2024. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdivo."},{"issue":"11","key":"10.1016\/j.clgc.2024.01.019_bib0017","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2024.01.019_bib0018","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.01.019_bib0019","unstructured":"Bavencio | European Medicines Agency. Accessed January 21, 2024. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bavencio."},{"key":"10.1016\/j.clgc.2024.01.019_bib0020","unstructured":"U.S. Food and Drug Administration. Avelumab for urothelial carcinoma maintenance treatment. Accessed January 21, 2024. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment."},{"key":"10.1016\/j.clgc.2024.01.019_bib0021","unstructured":"Programa d'Harmonitzaci\u00f3 Farmacoterap\u00e8utica. Atezolizumab per al tractament del carcinoma urotelial localment avan\u00e7at o metast\u00e0tic. 2018. Accessed December 4, 2022. Available at: https:\/\/scientiasalut.gencat.cat\/handle\/11351\/4271."},{"issue":"3","key":"10.1016\/j.clgc.2024.01.019_bib0022","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.019_bib0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2024.01.019_bib0024","article-title":"Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study","volume":"25","author":"Richters","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.019_bib0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-170149","article-title":"Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States","volume":"4","author":"Galsky","year":"2018","journal-title":"Bladder Cancer Amst Neth"},{"issue":"7","key":"10.1016\/j.clgc.2024.01.019_bib0026","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/13696998.2019.1591424","article-title":"Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma","volume":"22","author":"Aly","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.clgc.2024.01.019_bib0027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canep.2019.03.013","article-title":"Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting","volume":"60","author":"Simeone","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"12","key":"10.1016\/j.clgc.2024.01.019_bib0028","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/fon-2018-0654","article-title":"Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study","volume":"15","author":"Flannery","year":"2019","journal-title":"Future Oncol Lond Engl"},{"key":"10.1016\/j.clgc.2024.01.019_bib0029","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2020.00167","article-title":"Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre","volume":"10","author":"Cheeseman","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2024.01.019_bib0030","unstructured":"Bristol Myers Squibb provides update on CheckMate-901 trial evaluating opdivo (nivolumab) plus yervoy (ipilimumab) as first-line treatment for patients with unresectable or metastatic urothelial carcinoma. Accessed December 4, 2022. Available at: https:\/\/news.bms.com\/news\/corporate-financial\/2022\/Bristol-Myers-Squibb-Provides-Update-on-CheckMate\u2013901-Trial-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma\/default.aspx."},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.01.019_bib0031","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2022.40.6_suppl.487","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up results from the JAVELIN bladder 100 trial","volume":"40","author":"Powles","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2024.01.019_bib0032","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.01.019_bib0033","doi-asserted-by":"crossref","first-page":"S1341","DOI":"10.1016\/j.annonc.2023.10.107","article-title":"LBA7 nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial","volume":"34","author":"Van Der Heijden","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.019_bib0034","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2023.01.016","article-title":"Disease-free survival analysis for patients with high-risk muscle-invasive urothelial carcinoma from the randomized CheckMate 274 trial by PD-L1 combined positive score and tumor cell score","volume":"83","author":"Galsky","year":"2023","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.clgc.2024.01.019_bib0035","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T07:59:25Z","timestamp":1717660765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732400020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S155876732400020X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.019","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102047"}}